Elevance Health, Inc. (ELV) is valued at $76.5 billion and aims to improve the health of humanity through a broad healthcare portfolio. The company is set to report its fiscal 2025 fourth-quarter earnings at the end of January, with Wall Street analysts expecting EPS to decrease by 17%.

Despite challenges, Elevance Health serves over 109 million consumers nationwide and has a strong operating model. The company’s fiscal 2025 third-quarter earnings exceeded expectations, with revenue increasing by 12% year over year to $50.71 billion. Adjusted EPS beat estimates at $6.03, showcasing resilient execution.

Elevance Health shares have underperformed the market, declining 6% in the past year. However, the company’s focus on affordability and member experience, along with value-based care partnerships and digital solutions, positions it well for future growth. Wall Street analysts have a “Moderate Buy” consensus with an average price target of $387.63, indicating a 12.6% upside potential.

Read more at Yahoo Finance: What You Need To Know Ahead of Elevance Health’s Earnings Release